CN102268004B - Chlorophyllin salt compound and preparation method thereof - Google Patents
Chlorophyllin salt compound and preparation method thereof Download PDFInfo
- Publication number
- CN102268004B CN102268004B CN 201110167368 CN201110167368A CN102268004B CN 102268004 B CN102268004 B CN 102268004B CN 201110167368 CN201110167368 CN 201110167368 CN 201110167368 A CN201110167368 A CN 201110167368A CN 102268004 B CN102268004 B CN 102268004B
- Authority
- CN
- China
- Prior art keywords
- preparation
- salt compound
- present
- treatment
- low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention belongs to the field of heterocyclic compounds and particularly relates to a chlorophyllin salt compound and a preparation method thereof. The chlorophyllin salt compound is a novel photosensitizer which is stable in nature, high in photodynamic activity, low in skin toxicity and controllable in quality and is used for photodynamic treatment of cancers, infections and other diseases required to be treated by optical radiation. In the invention, the substituent of R3 is inform of a carboxylate, so the water solubility is high and the preparation of subsequent medicinal preparations is promoted; the absorption wavelength is more than 650 nanometers; the quantum yield of triplet state and the quantum yield of low singlet oxygen are high; the toxicity in darkness is low, and health of human body can be improved; the selectivity is high; the structure is clear and the performance is stable; and the fat water compatibility is high.
Description
Technical field
The invention belongs to the heterogeneous ring compound field, be specifically related to a kind of CHLOROPHYLLINE salt compound and preparation method thereof.
Background technology
(Photodynamic Therapy is to utilize photodynamic effect to carry out a kind of new technology of medical diagnosis on disease and treatment PDT) to photodynamic therapy.Its effect basis is photodynamic effect.This is a kind of photosensitization reaction of following biological effect that has oxygen molecule to participate in.Its process is, the photosensitizers that the laser radiation of specific wavelength absorbs tissue is excited, and the photosensitizers of excited state is given oxygen on every side transmission ofenergy, generate active very strong singlet oxygen, oxidizing reaction takes place in singlet oxygen and adjacent biomacromolecule, produce cytotoxic effect, and then cause cell impaired and even dead.
Photodynamic therapy is compared with conventional meanses such as operation, chemotherapy, radiotherapies as the new technology of oncotherapy, has many important advantage, demonstrates vital role in the complex therapy of tumour day by day.Up to now, this therapy is successfully in order to treat multiple malignant tumour, precancerous lesions such as oesophagus squamous atypical hyperplasia and Barrett oesophagus pathology, bronchiolar epithelium atypical hyperplasia, urinary bladder transitional epithelium atypical hyperplasia, and nontumorous benign lesion such as senile eyeground maculopathy, skin nevus flammeus, curative effect is encouraging, has a extensive future.
Existing 3 kinds of photosensitive drugs obtain the approval of U.S. food and Drug Administration (FDA) at present, be PHOTOFRIN (popular name porfimer sodium), Visudyne(popular name verteporfin, or chemical structure is called for short BPD-MA) and the 5-aminolevulinic acid (5-aminolaevulinic acid, ALA).
Up to now, PHOTOFRIN has obtained unique photosensitive drug that drugs approved by FDA can be applicable to multiple solid malignant treatment.This is a kind of porphyrin oligomer mixture that extracts and carry out chemical modification from ox blood.PHOTOFRIN is its trade(brand)name, this medicine now the U.S., Canada, etc. more than ten countries obtain the approval of medicine prison departments of government, can be respectively applied to the conventional treatment of some the tumor types patient in the esophageal carcinoma, lung cancer, bladder cancer, cervical cancer and the skin carcinoma.2 kinds of photosensitive drugs are the treatment that Visudyne and 5-aminolaevulinic acid are mainly used in non-neoplastic disease (senile eyeground maculopathy, photochemistry property keratosis) in addition.
But to the analysis revealed of PHOTOFRIN, its mesoporphyrin monomer: dimer: 22:23:55, the stratographic analysis of carrying out can obtain 60 peaks, thus can't carry out effective quality control, so clinical effectiveness difference is huge.Photosensitizers is the main medicine in the photodynamic therapy, China was from 1986, there is research institution of a few family just to begin research and development to anticancer photosensitizer, mainly from ox blood, extract protoheme again by the semi-synthetic active drug (the happiness pool divides) that obtains, kill and wound cancer cells with the laser combined utilization again.But because the effective constituent that the happiness pool is divided is unclear fully, therefore, the happiness pool divides as first-generation anticancer photosensitizer on applying, and does not get a desired effect.
At present, the U. S. application people has all related to a kind of water-soluble porphyrin for photodynamic therapy, the R of this porphyrin in patent " for water-soluble porphyrin derivative, its purposes, the preparation of optical dynamic therapy " (patent No. 02811141.9) and the patent application " preparation method who is used for the water-soluble porphyrin of photodynamic therapy " (number of patent application 200910130260.X) of China
5, R
6Substituting group be alkyl substituent, cause the water-soluble relatively poor of this porphyrin, in follow-up pharmaceutical preparation comparatively the difficulty.
In sum, clinical needs have the photosensitive drug of following characteristics: 1, absorbing wavelength is greater than 650 nanometers; 2, the quantum yield that has higher triplet state quantum yield and single low heavy attitude oxygen; 3, has low dark toxicity; 4, selectivity height; 5, clear and definite, the stable performance of structure; 6, has good fat, the water compatibility.
Summary of the invention
The invention provides a kind of CHLOROPHYLLINE salt compound and preparation method thereof, the present invention is that a kind of stable in properties, photodynamic activity are strong, little, the quality controllable novel photosensitive agent of skin phototoxicity, is used for cancer, infection and other needs the photodynamic therapy of the disease of optical radiation treatment.
The objective of the invention is to be achieved through the following technical solutions:
A kind of CHLOROPHYLLINE salt compound, general formula is as follows:
Wherein, R
1Be independently selected from C
1-18Alkyl, C
1-18Alkenyl, C
1-8Alkoxyl group and C
1-18Acyl group, it is randomly replaced by one or more substituting groups that are selected from halogen and hydroxyl; R
2Be Na
+, carboxylic acid sodium or glucoside; R
3Be H, carboxyl or carboxylic acid sodium.
In preferred embodiments, R
1Be independently selected from CH
2(CH
2)
4CH
3, R
2Be Na
+, carboxylic acid sodium or glucoside, R
3Be H or carboxyl.
The example of water-soluble CHLOROPHYLLINE salt compounds of the present invention includes, but are not limited to:
（I）
（II）
The objective of the invention is to be achieved through the following technical solutions:
The invention provides the method for preparing the CHLOROPHYLLINE salt compounds, may further comprise the steps:
I, pheophorbide is converted into acid porphyrin;
II, with described acid porphyrin derivatize, obtain the complexing acid porphyrin of deriving;
III, make the described complexing acid porphyrin of deriving obtain the CHLOROPHYLLINE salt compound with reaction in the medium that is selected from water and aqueous organic solution.
The miscible solvent of the alkali aqueous solution of the employing in step I, the II is:
One or more mixtures in lower alkane alcohols, polyalcohols, ring-type ethers, ketone, nitrile, amides, sulfoxide class, sulfone class, the gylcol ether.
Described lower alkane alcohols is one or more mixtures in methyl alcohol, ethanol, n-propyl alcohol, the Virahol; Described polyalcohols is ethylene glycol, 1, one or more mixtures in 2-propylene glycol, the glycerine;
Described ring-type ethers is one or more mixtures in tetrahydrofuran (THF), dioxane, the morpholine; Described ketone is acetone; Described nitrile is one or more mixtures in acetonitrile, the succinonitrile; Described amides is methane amide, N, one or more mixtures in the dinethylformamide; Described sulfone class is tetramethylene sulfone; Described sulfoxide class methyl-sulphoxide; Described gylcol ether is one or more mixtures in methyl glycol, glycol monoethyl ether, the glycol ether.
Reaction described in the step II can be carried out under the temperature of wide region, for example 0-90 ℃, preferred 10-65 ℃, more preferably 15-60 ℃, for example carries out under 15-25 ℃; According to used condition, the reaction times was generally dozens of minutes to several days in the step II, a few hours for example, for example 4-24 hour, for example 12 hours.
On the other hand, the invention provides compound as photosensitive drug.
On the other hand, the invention provides a kind of photosensitive drug for photodynamic therapy, it comprises compound of the present invention or mixture of the present invention, and randomly comprises one or more pharmaceutically useful vehicle.
On the other hand, the invention provides the purposes of CHLOROPHYLLINE salt compounds, namely be used for the treatment of as photosensitive drug or diagnosing malignant tumor, precancerous lesion or benign lesion.
On the other hand, the invention provides the method for the treatment of malignant tumour, precancerous lesion or benign lesion, it comprises compound of the present invention or mixture of the present invention or its pharmaceutical composition of using significant quantity to described individuality, and imposes the rayed of the specific wavelength of significant quantity.
The present invention has following beneficial effect compared to existing technology:
R of the present invention
3Substituting group be the form of carboxylate salt, water-soluble strong, be conducive to prepare follow-up pharmaceutical preparation; Absorbing wavelength of the present invention is greater than 650 nanometers; The present invention has the quantum yield of higher triplet state quantum yield and single low heavy attitude oxygen; The present invention has low dark toxicity, is conducive to HUMAN HEALTH; Selectivity height of the present invention; Structure of the present invention is clear and definite, stable performance; The present invention has good fat water compatibility.
Embodiment
Embodiment 1:
A kind of CHLOROPHYLLINE salt compound, general formula is as follows:
Wherein, R
1Be independently selected from C
1-18Alkyl, C
1-18Alkenyl, C
1-8Alkoxyl group and C
1-18Acyl group, it is randomly replaced by one or more substituting groups that are selected from halogen and hydroxyl; R
2Be Na
+, carboxylic acid sodium or glucoside; R
3Be H, carboxyl or carboxylic acid sodium.
In preferred embodiments, R
1Be independently selected from CH
2(CH
2)
4CH
3, R
2Be Na
+, carboxylic acid sodium or glucoside, R
3Be H or carboxyl.
[0023]The example of the water-soluble CHLOROPHYLLINE salt compounds of present embodiment includes but not limited to:
（I）
（II）
The preparation method of above-mentioned CHLOROPHYLLINE salt compounds may further comprise the steps:
I, pheophorbide is converted into acid porphyrin;
II, with described acid porphyrin derivatize, obtain the complexing acid porphyrin of deriving;
III, make the described complexing acid porphyrin of deriving obtain the CHLOROPHYLLINE salt compound with reaction in the medium that is selected from water and aqueous organic solution.
The miscible solvent of the alkali aqueous solution of the employing in step I, the II is:
One or more mixtures in lower alkane alcohols, polyalcohols, ring-type ethers, ketone, nitrile, amides, sulfoxide class, sulfone class, the gylcol ether.
Described lower alkane alcohols is one or more mixtures in methyl alcohol, ethanol, n-propyl alcohol, the Virahol; Described polyalcohols is ethylene glycol, 1, one or more mixtures in 2-propylene glycol, the glycerine;
Described ring-type ethers is one or more mixtures in tetrahydrofuran (THF), dioxane, the morpholine; Described ketone is acetone; Described nitrile is one or more mixtures in acetonitrile, the succinonitrile; Described amides is methane amide, N, one or more mixtures in the dinethylformamide; Described sulfone class is tetramethylene sulfone; Described sulfoxide class methyl-sulphoxide; Described gylcol ether is one or more mixtures in methyl glycol, glycol monoethyl ether, the glycol ether.
Reaction described in the step II can be carried out under the temperature of wide region, for example 0-90 ℃, preferred 10-65 ℃, more preferably 15-60 ℃, for example carries out under 15-25 ℃; According to used condition, in 0.5-120 hour reaction times, be preferably 4-24 hour, more preferably 12 hours in the step II.
On the other hand, present embodiment provides the compound as photosensitive drug.
On the other hand, present embodiment provides a kind of photosensitive drug for photodynamic therapy, and it comprises compound of the present invention or mixture of the present invention, and randomly comprises one or more pharmaceutically useful vehicle.
On the other hand, present embodiment provides the purposes of CHLOROPHYLLINE salt compounds, namely is used for the treatment of as photosensitive drug or diagnosing malignant tumor, precancerous lesion or benign lesion.
On the other hand, present embodiment provides the method for the treatment of malignant tumour, precancerous lesion or benign lesion, it comprises compound of the present invention or mixture of the present invention or its pharmaceutical composition of using significant quantity to described individuality, and imposes the rayed of the specific wavelength of significant quantity.
The R of the CHLOROPHYLLINE salt compound of present embodiment
3Substituting group be the form of carboxylate salt, water-soluble strong, be conducive to prepare follow-up pharmaceutical preparation; Absorbing wavelength is greater than 650 nanometers; Quantum yield with higher triplet state quantum yield and single low heavy attitude oxygen; Originally have low dark toxicity, be conducive to HUMAN HEALTH; Selectivity height of the present invention; Structure is clear and definite, stable performance; Has good fat water compatibility.
Among following examples 2-4, for those of ordinary skill in the art provides comprehensive and illustrative description, described how to prepare CHLOROPHYLLINE salt compounds of the present invention, and for the preparation of pharmaceutical composition, these embodiment limit the scope of the invention.Though in experiment, guarantee the accuracy of the data (for example quantity, temperature etc.) of use, also should consider some experimental error and deviation as far as possible.
Embodiment 2:
Present embodiment is raw material with silkworm excrement chlorophyll, and preparation 2-removes vinyl-2-(the own hydroxyethyl of 1-)-pyropheophorbide-a sodium (1).
I, pheophorbide is converted into acid porphyrin:
A, preparation pheophorbide-a methyl esters:
200g silkworm excrement chlorophyll is dissolved in the methanol solution that 4000mL contains 5% sulfuric acid; 15-25 ℃ of lucifuge carried out stir process 12 hours under nitrogen protection again; Carry out filtration treatment again; Add water and methylene dichloride again and carry out extraction treatment; Again the organic phase water is carried out carrying out washing treatment; Carry out drying treatment, concentrating under reduced pressure processing again; Again the enriched material that obtains is carried out the silica gel column chromatography separating treatment, during described chromatographic separation is handled, eluent is sherwood oil and ethyl acetate, the volume ratio of described sherwood oil and ethyl acetate is 3:1, obtain blackish green solid A6.9g, wherein contain described pheophorbide-a methyl esters, productive rate is 85%.UV-vis?(CHCl
3)?λmax?:?407(1.0),?503?(0.03),?532?(0.02),?610?(0.02),?667?(0.39)?nm;?IR?(?KBr?)?ν:?2946-2843?(?C-H?),?1736?(?C=C?),?1640?(?C=N?),?1624?(?C=C?)?cm
-1;?
1H?NMR?(CDCl
3)?δ:?-1.68?(1H,?NH),?0.52(?1H,?NH),?1.70?(d,?J=7.5?Hz,?3H,?18-CH
3),?1.82?(t,?J=7.5Hz,?3H,?8
2-CH
3),?2.17-2.40?(m,?2H?17
1-CH
2),2.43-2.78?(m,2H,?17
2-H),?3.26,?3.40,?3.58,?3.67?(12H,?CH
3),?3.72?(q,?J=7.5?Hz,?2H,8
1-CH
2),?3.86?(s,?3H,?13
2-OCH
3),?4.20-4.36?(m,?1H,?17-H),?4.38-4.50?(m,?1H,?18-H),?6.24?(s,?1H,?13
2-H),6.16?(d,?J=11.5?Hz,?1H,?3
2b-H?),?6.29?(d,?J=17.5?Hz,?1H,?32a-H),?8.03?(m,?1H,?3
1-H),?8.57,?9.41,?9.53(?each?s,?1H,?meso-H?)。
II, with described acid porphyrin derivatize, obtain the complexing acid porphyrin of deriving;
A, preparation pyropheophorbide-a methyl esters:
The described blackish green solid A of 2.0g (3.3mmol) is dissolved with 200 mL glacial acetic acids, in stirring, carry out back flow reaction 4 h again; Carry out underpressure distillation again and handle, steam except most of acetic acid; Add 200 mL water again, (3 * 60 ml) carries out extraction treatment with methylene dichloride; Again organic phase is carried out drying back concentrating under reduced pressure; The gained enriched material being carried out silica gel column chromatography separates in the described chromatographic separation processing again, eluent is sherwood oil and ethyl acetate, the volume ratio of described sherwood oil and ethyl acetate is 3:1, obtain blackish green solid B (1.5g, 2.80mmol), wherein contain described pyropheophorbide-a methyl esters, productive rate is 85%.UV-vis?(CHCl
3)?λmax:?411?(1.0),?669?(0.39)?nm;IR(?KBr?)?ν:?2935-2846(?C-H?),?1736?(?C=C?),?1643?(?C=N?),?1619?(?C=C?)?cm
-1;?
1H?NMR?(CDCl
3)?δ:?-1.68?(1H,?NH),?0.49?(1H,?NH),1.69?(d,?J=7.5?Hz,?3H,?18-CH
3),?1.80?(t,?J=7.5?Hz,?3H,?8
2-CH
3),?2.14-2.38?(m,?2H?17
1-CH
2),?3.24,3.42,?3.66,?3.62(12H,?CH3),2.41-2.82?(m,2H,?17
2-CH
2),?3.70?(q,?J=7.5?Hz,?2H,?8
1-CH2),?4.17-4.38?(m,?1H,?17-H)?4.40-4.53?(m,?1H,?18-H),?5.15?(d,?J=20.0?Hz,?1H,?13
2-H),?5.26?(1H,?13
2-H),?6.19-?6.26?(m,?2H,?3
2-H),?8.00?(m,?1H,?3
1-H),?8.58,?9.45,?9.56?(?s,?1H,?meso-H?)。
B, preparation 2-remove vinyl-2-(the own hydroxyethyl of 1-)-pyropheophorbide-a methyl esters:
With the described blackish green solid B of 500mg (0.93mmol) with the dissolving of 30% Hydrogen bromide glacial acetic acid (12.5 milliliters), then at 15-25 ℃ of stirring reaction 3 h; Carry out vacuum decompression again and handle, desolventizing gets and mainly contains the solid that 2-removes vinyl-2-(1-bromotrifluoromethane)-pyropheophorbide-a methyl esters; Above-mentioned mainly containing added 7.5 milliliters of n-hexyl alcohols in the solid that 2-removes vinyl-2-(1-bromotrifluoromethane)-pyropheophorbide-a methyl esters, add 60 milliliters of anhydrous methylene chlorides and 200 milligrams of Anhydrous potassium carbonates again; Reaction added 500 milliliters of methylene dichloride after 1 hour under nitrogen protection again; Again with the organic layer evaporate to dryness; Carry out the alumina column chromatography separating treatment again, during described chromatographic separation is handled, eluent is sherwood oil and acetone, the volume ratio of described sherwood oil and acetone is 4:1, namely get target product, wherein contain described 2-and go that vinyl-2-(the own hydroxyethyl of 1-)-pyropheophorbide-a methyl esters productive rate is 55%.UV-vis?(CHCl
3)λmax:?410?(1.00),?505?(0.10),?536?(0.10),?667?(0.45)?nm;?IR?(KBr)?v:?2985-2870?(C-H),?1742,1708?(C=O),?1640?(C=N),?1620?(C=C)?cm
-1；
1H?NMR?(CDCl
3)?δ:?9.70,?9.53,?8.51?(each?s,?each?1H,?meso-H),?6.25-6.43?(m,?1H,3
1-H),?6.25?(s,1H,?13
2-H),?4.45-4.49?(?1H,?17-H),?4.15-4.26?(1H,?18-H),?3.88,?3.69,?3.55,?3.40,?3.23(each?s,?each?3H,?CH
3),?3.70?(q,?J=7.5?Hz,?8
1-CH
2),?2.18?(d,?J?=?7.0?Hz,?3
1-CH3),?2.00-2.70?(4H,?17-CH
2),?1.81?(t,?J=7.0?Hz,?8-CH
3),?1.73?(d,?J=7.5?Hz,?18-CH
3),?0.50,?-1.70?(each?br?s,?each1H,?NH)。
III, make the described complexing acid porphyrin of deriving obtain the CHLOROPHYLLINE salt compound with reaction in the medium that is selected from water and aqueous organic solution:
A, preparation 4,2-remove vinyl-2-(the own hydroxyethyl of 1-)-pyropheophorbide-a sodium:
Make its whole dissolvings with adding 20 ml tetrahydrofuran (THF)s in the described target product of 100mg, add 4 ml, 0.2 mol/L aqueous sodium hydroxide solution again, place again and spend the night; Carry out reduced pressure treatment again, desolventizing obtains reaction product; Described reaction product is packed in the apparatus,Soxhlet's, and acetone refluxes, and gained acetone phegma evaporate to dryness namely gets target compound (1):
Each raw material, reagent and equipment are the market conventional products in the present embodiment.
Embodiment 3:
Present embodiment is raw material with silkworm excrement chlorophyll, and preparation 2-removes vinyl-2-(the own hydroxyethyl of 1-)-pheophorbide-a disodium (2).
I, pheophorbide is converted into acid porphyrin:
A, preparation pheophorbide-a methyl esters:
100g silkworm excrement chlorophyll is dissolved in the methanol solution that 2000mL contains 5% sulfuric acid; Carried out stir process 12 hours in nitrogen protection 15-25 ℃ lucifuge again; Carry out filtration treatment again; Add water and methylene dichloride again and carry out extraction treatment; Again the organic phase water is carried out carrying out washing treatment; Carry out drying treatment, concentrating under reduced pressure processing again; Again the enriched material that obtains is carried out the silica gel column chromatography separating treatment, during described chromatographic separation is handled, eluent is sherwood oil and ethyl acetate, the volume ratio of described sherwood oil and ethyl acetate is 3:1, obtain blackish green solid A3.50g, wherein contain described pheophorbide-a methyl esters, productive rate is 85%.UV-vis?(CHCl
3)?λmax?:?407(1.0),?503?(0.03),?532?(0.02),?610?(0.02),?667?(0.39)?nm;?IR?(?KBr?)?ν:?2946-2843?(?C-H?),?1736?(?C=C?),?1640?(?C=N?),?1624?(?C=C?)?cm
-1;?
1H?NMR?(CDCl
3)?δ:?-1.68?(1H,?NH),?0.52(?1H,?NH),?1.70?(d,?J=7.5?Hz,?3H,?18-CH
3),?1.82?(t,?J=7.5Hz,?3H,?8
2-CH
3),?2.17-2.40?(m,?2H?17
1-CH
2),2.43-2.78?(m,2H,?17
2-H),?3.26,?3.40,?3.58,?3.67?(12H,?CH
3),?3.72?(q,?J=7.5?Hz,?2H,8
1-CH
2),?3.86?(s,?3H,?13
2-OCH
3),?4.20-4.36?(m,?1H,?17-H),?4.38-4.50?(m,?1H,?18-H),?6.24?(s,?1H,?13
2-H),6.16?(d,?J=11.5?Hz,?1H,?3
2b-H?),?6.29?(d,?J=17.5?Hz,?1H,?32a-H),?8.03?(m,?1H,?3
1-H),?8.57,?9.41,?9.53(?each?s,?1H,?meso-H?)。
II, with described acid porphyrin derivatize, obtain the complexing acid porphyrin of deriving:
A, 2,2-go the preparation of vinyl-2-(the own hydroxyethyl of 1-)-pheophorbide-a dimethyl ester:
With the Hydrogen bromide glacial acetic acid dissolving of the described blackish green solid A of 1.0 g (0.93mmol) with 25ml30%, then at stirring reaction 3 h; Carry out vacuum decompression again and handle, desolventizing gets and mainly contains the solid that 2-removes vinyl-2-(1-bromotrifluoromethane)-pheophorbide-a dimethyl ester; Add 15 milliliters of n-hexyl alcohols in the solid that 2-removes vinyl-2-(1-bromotrifluoromethane)-pheophorbide-a dimethyl ester to above-mentioned mainly containing again, add 100 milliliters of anhydrous methylene chlorides and 500 milligrams of Anhydrous potassium carbonates again; Reaction added 1000 milliliters of methylene dichloride, with the organic layer evaporate to dryness after 1 hour under nitrogen protection again; Carry out the alumina column chromatography separating treatment again, during described chromatographic separation is handled, eluent is sherwood oil and acetone, the volume ratio of described sherwood oil and acetone is 4:1, namely get target product, wherein contain described 2,2-and remove vinyl-2-(the own hydroxyethyl of 1-)-pheophorbide-a dimethyl ester, productive rate is 60%.
UV-vis?(CHCl
3)λmax:?410?(1.00),?505?(0.10),?536?(0.10),?667?(0.45)?nm;?IR?(KBr)?v:?2985-2870?(C-H),?1742,1708?(C=O),?1640?(C=N),?1620?(C=C)?cm
-1；
1H?NMR?(CDCl
3)?δ:?9.70,?9.53,?8.51?(each?s,?each?1H,?meso-H),?6.25-6.43?(m,?1H,3
1-H),?6.25?(s,1H,?13
2-H),?4.45-4.49?(?1H,?17-H),?4.15-4.26?(1H,?18-H),?3.88（s,?6?H,?CH
3）,?3.69,?3.55,?3.40,?3.23(each?s,?each?3H,?CH
3),?3.70?(q,?J=7.5?Hz,?8
1-CH
2),?2.18?(d,?J?=?7.0?Hz,?3
1-CH3),?2.00-2.70?(4H,?17-CH
2),?1.81?(t,?J=7.0?Hz,?8-CH
3),?1.73?(d,?J=7.5?Hz,?18-CH
3),?0.50,?-1.70?(each?br?s,?each1H,?NH)。
III, make the described complexing acid porphyrin of deriving obtain the CHLOROPHYLLINE salt compound with reaction in the medium that is selected from water and aqueous organic solution:
A, 3,2-go the preparation of vinyl-2-(the own hydroxyethyl of 1-)-pheophorbide-a disodium (2):
Make its whole dissolvings with adding 40 ml tetrahydrofuran (THF)s in the described target product of 200mg, add 10 ml, 0.2 mol/L aqueous sodium hydroxide solution again, place again and spend the night; Carry out reduced pressure treatment again, desolventizing obtains reaction product; Described reaction product is packed in the apparatus,Soxhlet's, and acetone refluxes, and gained acetone phegma evaporate to dryness namely gets target compound (II):
Each raw material, reagent and equipment are the market conventional products in the present embodiment.
Embodiment 4:
Present embodiment is that the detected result of embodiment 2, embodiment 3: 2-goes vinyl-2-(the own hydroxyethyl of 1-)-pyropheophorbide-a sodium (1) and 2-to go vinyl-2-(the own hydroxyethyl of the 1-)-pheophorbide-photosensitization of a disodium (2) in the acellular system.
The photosensitization of compound judges that this compound is as the possibility of photo-dynamical medicine in heavy water, reference [Xu Deyu etc., the The 2nd Army Medical College journal, 1988,9(5): 435 and Li Yixin etc., Acta Biophysica Sinica, 1985,1(4): 257] described method, having compared 2-goes vinyl-2-(the own hydroxyethyl of 1-)-pyropheophorbide-a sodium (1) and 2-to go vinyl-2-(the own hydroxyethyl of 1-)-pheophorbide-a disodium (2) to the sensitization effect of NADPH photooxidation, to the results are shown in following table in heavy water.
According to The above results, 2-goes vinyl-2-(the own hydroxyethyl of 1-)-pyropheophorbide-a sodium (1) and 2-to go the photooxidation of vinyl-2-(the own hydroxyethyl of 1-)-pheophorbide-a disodium (2) all to be better than HpD.
Claims (2)
1.
A kind of CHLOROPHYLLINE salt compound is characterized in that:
Structural formula is:
2. CHLOROPHYLLINE salt compound is characterized in that:
Structural formula is:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110167368 CN102268004B (en) | 2011-06-21 | 2011-06-21 | Chlorophyllin salt compound and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110167368 CN102268004B (en) | 2011-06-21 | 2011-06-21 | Chlorophyllin salt compound and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102268004A CN102268004A (en) | 2011-12-07 |
| CN102268004B true CN102268004B (en) | 2013-08-21 |
Family
ID=45050481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110167368 Active CN102268004B (en) | 2011-06-21 | 2011-06-21 | Chlorophyllin salt compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102268004B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104086554B (en) * | 2014-05-30 | 2016-02-17 | 桂林晖昂生化药业有限责任公司 | A kind of novel completely water-soluble photosensitizers monomer and preparation method thereof and application |
| CN104193753A (en) * | 2014-08-26 | 2014-12-10 | 江苏红豆杉药业有限公司 | Method for preparing photosensitizer HPPH from taxus chinensis branch and leaf extracts |
| CN104744482A (en) * | 2015-03-17 | 2015-07-01 | 易晓阳 | Novel chlorophyllin as well as preparation method and application thereof |
| CN106083872B (en) * | 2016-05-25 | 2019-02-19 | 中国人民解放军第二军医大学 | Purpurin 18 ether derivative and its preparation method and application |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63264420A (en) * | 1988-03-11 | 1988-11-01 | Green Cross Corp:The | Antiulcer agent containing thiamine cobaltichlorophylin complex compound |
| DE19814405C2 (en) * | 1998-03-31 | 2000-03-02 | Schastak Astrid | Porphyrins and their use as photosensitizers |
| US20030004334A1 (en) * | 2001-06-01 | 2003-01-02 | Ceramoptec Industries, Inc. | Water-soluble porphyrin derivatives and methods of their preparation |
| KR100484205B1 (en) * | 2003-01-16 | 2005-04-20 | 주식회사 테크노마트 | Porphyrin derivatives |
-
2011
- 2011-06-21 CN CN 201110167368 patent/CN102268004B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102268004A (en) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6832358B2 (en) | 5-Aminolevulinic acid and derivatives salts | |
| CN105585571B (en) | A kind of mono-substituted phthalocyanine Zn complex in periphery and its adriamycin conjugate | |
| JPS625985A (en) | Novel tetrapyrrole compound | |
| EP1420824A2 (en) | Compound | |
| CN113461697B (en) | Chlorin compound and preparation method and application thereof | |
| CA2353554C (en) | Palladium-substituted bacteriochlorophyll derivatives and use thereof | |
| JP7043260B2 (en) | A novel dihydroporphyrin e6 derivative and a pharmaceutically acceptable salt thereof, a method for preparing the same and a use thereof. | |
| CN102268004B (en) | Chlorophyllin salt compound and preparation method thereof | |
| BG108534A (en) | Photosensitiser and method for production thereof | |
| JP2005500335A (en) | Porphyrin derivatives used in photodynamic therapy | |
| WO2021143829A1 (en) | Non-peripheral quaternary ammonium group modified zinc phthalocyanine and method for preparation thereof and application thereof | |
| CN106046008A (en) | Chlorin p6 amino acid derivative, preparation method therefor and use of chlorin p6 amino acid derivative | |
| CN113831351A (en) | Novel tetrapyrrole derivatives and application thereof | |
| CN104844645B (en) | A kind of silicon phthalocyanine of axial ALA modifications and its preparation method and application | |
| CN106083872B (en) | Purpurin 18 ether derivative and its preparation method and application | |
| CN102260269B (en) | Dendrimer containing porphyrin or chlorine and its application | |
| CN104744482A (en) | Novel chlorophyllin as well as preparation method and application thereof | |
| CN108864116A (en) | A kind of novel chlorin e 6 derivative and the preparation method and application thereof | |
| CN109651383B (en) | Compounds for photosensitizers and uses thereof | |
| CN1081621C (en) | Amino substituted demethoxy hypocrellin and its preparing method | |
| CN1092198C (en) | 2-mercapto-ethylamine cyclized hypocrellin and preparation process and usage thereof | |
| EP1860107A1 (en) | Photosensitive compound | |
| CN111825685B (en) | Hematoporphyrin monofluoroalkyl diether and fluorophenyl alkyl diether derivatives and application thereof in medicine field | |
| CN104292235B (en) | 2-(the positive hexyloxy of 1-) ethyl chlorin f salt and pharmaceutical composition thereof and purposes | |
| CN102827226A (en) | Silicon phthalocyanine modified by uridine derivatives and preparation method and application of silicon phthalocyanine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180723 Address after: 100054 floor 12, building 21, Xicheng District plain, Beijing, A1305 Patentee after: TAI YANG SHENG HIGH-TECH PHARMACEUTICAL RESEARCH Co.,Ltd. Address before: 100054 room 1307, block B, Yatai center, 21 Caishikou Avenue, Xuanwu District, Beijing. Patentee before: BEIJING PURUIBOSI INVESTMENT Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 100054 floor 12, building 21, Xicheng District plain, Beijing, A1305 Patentee after: Beijing Taiyangsheng high tech Pharmaceutical Research Co.,Ltd. Address before: 100054 floor 12, building 21, Xicheng District plain, Beijing, A1305 Patentee before: TAI YANG SHENG HIGH-TECH PHARMACEUTICAL RESEARCH Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211026 Address after: 236800 5th floor, caohong Road comprehensive office building, high tech Zone, Bozhou City, Anhui Province Patentee after: Taiyangsheng (Bozhou) Biomedical Technology Co.,Ltd. Address before: 100054 floor 12, building 21, Xicheng District plain, Beijing, A1305 Patentee before: Beijing Taiyangsheng high tech Pharmaceutical Research Co.,Ltd. |